41S RIO GRANDE STREET, SALT LAKE CITY, UT
Other Events
Reports Second Quarter 2025 Financial Results and Provides Business Update
Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Shareholder votes
Costs of Shutting Down or Selling Parts of the Business, Reg. FD
News, Legal Opinion
Reports First Quarter 2025 Financial Results and Provides Business Update
Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)